Atopic Dermatitis

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Latest News

Atopic Dermatitis Itch. | Image Credit: Pormezz - stock.adobe.com .jpeg
Top Risk Factors for Anxiety, Depression Identified in Atopic Dermatitis

July 1st 2025

This new study identifies key contributors to mental health decline in individuals with atopic dermatitis, highlighting the need for integrated care.

Air pollution and atopic dermatitis | Image Credit: Maggie Shaw-sora.chatgpt.com
Air Pollution Linked to Worse Atopic Dermatitis

June 27th 2025

Atopic dermatitis diagnosis | Image Credit: MP Studio-stock.adobe.com
Dupilumab for Atopic Dermatitis May Increase Psoriasis Risk

June 18th 2025

Pediatric atopic dermatitis | Image Credit: Maggie L. Shaw/sora.chatgpt.com
Pediatric Atopic Dermatitis Linked to Allergy Development

June 13th 2025

Atopic Dermatitis Image Credit: wladimir1804-stock.adobe.com
Oral Ivarmacitinib Shows Promise in Atopic Dermatitis

June 6th 2025

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives

More News

Health cross symbol.
January 27th 2022

Dupilumab Significantly Reduces Hospitalization Rates in Patients With Atopic Dermatitis

Matthew Gavidia
Patients with atopic dermatitis (AD) treated with dupilumab showed reduced hospitalization rates and shorter duration of AD-related hospitalizations vs those treated with control therapies.
Health care cost.
January 21st 2022

Substantial Cost Burden, Health Care Utilization Found in Patients With Severe Atopic Dermatitis

Matthew Gavidia
Patients with atopic dermatitis were associated with significant economic burden primarily driven by outpatient visits and pharmacy use, which increased with disease severity.
Physician, parent, and sick child.
January 19th 2022

Early-Life Infection Linked With Atopic Dermatitis Development in Infants, Children

Matthew Gavidia
Incidence of infectious diseases, skin infections, and systemic antibiotic exposure were all associated with the development of atopic dermatitis among infants and young children.
Spotlighting a patient.
January 13th 2022

Greater Risk of COVID-19 Infection Found in Patients With Atopic Dermatitis

Matthew Gavidia
Patients with atopic dermatitis were shown to be more likely to receive a COVID-19 diagnosis than the general population.
Child with mask.
January 11th 2022

Atopic Dermatitis Associated With Behavioral Issues in Children and Adolescents

Matthew Gavidia
Children and adolescents with atopic dermatitis (AD) tended to have a higher number of delinquent behaviors than those without AD, including fighting, cheating on exams, and suspension.
Person grasping hand.
January 6th 2022

Real-World Study Finds Dupilumab Safe, Effective for Moderate-to-Severe Atopic Dermatitis

Matthew Gavidia
Korean patients with moderate-to-severe atopic dermatitis achieved and maintained markedly improved skin clearance with dupilumab treatment in a real-world setting, including in the face and hands.
David R. Stukus, MD, FACAAI.
December 28th 2021

Dr David R. Stukus Spotlights Unmet Needs in Atopic Dermatitis Management

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the lack of interventions to manage the underlying causes of exacerbation in atopic dermatitis.
Nurse and medical provider.
December 24th 2021

Evaluating Differences in Therapeutic, Diagnostic Approaches to Atopic Dermatitis

Matthew Gavidia
A study found significant differences in the therapeutic and diagnostic approaches to atopic dermatitis used by allergists, dermatologists, and pediatricians, and those recommended by guidelines.
David R. Stukus, MD, FACAAI.
December 22nd 2021

Dr David R. Stukus Discusses Access, Affordability Concerns of Emerging Atopic Dermatitis Therapies

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the difficulties of gaining coverage for newer biologic therapies in the treatment of atopic dermatitis.
Happy child.
December 18th 2021

Dupilumab Shows High Effectiveness in AD for Ages 6 Months and Up

Matthew Gavidia
Research presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference said dupilumab (Dupixent) is an effective and safe therapeutic option in adults, adolescents aged 6 to 11 years, and young children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
David R. Stukus, MD, FACAAI.
December 17th 2021

Dr David R. Stukus on Immune-Related Response to Therapy in Atopic Dermatitis

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses efforts to align novel treatments for atopic dermatitis with patients based on the underlying mechanisms of disease.
Many Questions Remain in Deciphering, Preventing Atopic March
December 14th 2021

Many Questions Remain in Deciphering, Preventing Atopic March

Jared Kaltwasser
In a new review article, investigators outline the challenges to studying the disease, but also point to big data as an important tool moving forward.
Person closing eye.
December 9th 2021

Patients With Atopic Dermatitis More Prone to Depression, Anxiety

Matthew Gavidia
Patients with atopic dermatitis, particularly those with more severe skin manifestations, were shown to be at greater risk of depression and anxiety compared with the general population.
Child in a hospital bed.
December 7th 2021

Increased Risk of Fracture Found in Children With Atopic Dermatitis

Matthew Gavidia
Children with atopic dermatitis were shown to be at an increased risk of fractures compared with the general population, with systemic use of corticosteroid and antihistamine therapy cited as mediating factors.
Patient and physician.
December 3rd 2021

Higher Risk of Systemic, Psychiatric Conditions Found in Patients With Atopic Dermatitis

Matthew Gavidia
A high comorbidity burden, including psychiatric, autoimmune, and systemic conditions, was found in US adult ambulatory populations with atopic dermatitis.
Doctor looking at electronic medical record.
December 1st 2021

Dupilumab-Induced Ophthalmic Disease Common in Adults With Atopic Dermatitis

Matthew Gavidia
More than 1 in 3 patients with atopic dermatitis reported incidence of dupilumab-induced ocular surface disease (DIOSD), with asthma and family history of AD shown to further increase the risk of developing DIOSD.
Human eye.
November 25th 2021

Atopic Dermatitis Severity, Age at Diagnosis May Increase Risk of Ophthalmic Diseases

Matthew Gavidia
Moderate-to-severe disease, childhood onset, and systemic treatments were all associated with a greater risk of conjunctivitis in patients with atopic dermatitis, whereas use of soft and hard contact lenses were linked with risk of keratitis.
Physician on a computer.
November 23rd 2021

Machine Learning Approach Finds Several Severity-Associated Factors in Atopic Dermatitis

Matthew Gavidia
Findings of a machine learning-based deep phenotyping approach found a myriad of factors associated with severe disease in atopic dermatitis, including age between 12 and 21 years or older than 52 years, lack of physical activity, and incidence of alopecia areata.
Jonathan Silverberg, MD, PhD, MPH, George Washington University School of Medicine and Health Sciences.
November 17th 2021

Dr Jonathan Silverberg on Potential Benefits, Challenges of JAK Inhibitor Use in Atopic Dermatitis

Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, explains efficacy and safety implications of JAK inhibitor use for atopic dermatitis.
Vaccination needle.
November 10th 2021

Flu Vaccine May Decrease Asthma Risk in Patients With Atopic Dermatitis

Matthew Gavidia
Adults with atopic dermatitis were shown to be at lower risk of developing asthma if they were vaccinated against influenza, particularly those who adhered to yearly shots.
onathan Silverberg, MD, PhD, MPH, George Washington University School of Medicine and Health Sciences
November 9th 2021

Dr Jonathan Silverberg Explains JAK/STAT Pathway Involvement in Atopic Dermatitis

Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, discusses the involvement of the JAK/STAT pathway in the pathogenesis of atopic dermatitis.
Child with parent and physician.
November 4th 2021

Children With Atopic Dermatitis More Prone to Depression, Internalizing Behaviors

Matthew Gavidia
Children with severe atopic dermatitis were shown to be at nearly 2-fold greater risk of both depression and internalizing behaviors, with mild disease also associated with internalizing behaviors in those as young as 4 years of age.
Child in hospital bed.
November 1st 2021

Prenatal Exposure to Metals May Increase Risk of Atopic Dermatitis in Children

Matthew Gavidia
Prenatal exposure to inorganic arsenic and coexposure to inorganic arsenic and cadmium was found to increase risk of atopic dermatitis by up to 2.42-fold in young Taiwanese children.
Ruxolitinib Cream Approved for Short-term Treatment of Atopic Dermatitis
September 22nd 2021

Ruxolitinib Cream Approved for Short-term Treatment of Atopic Dermatitis

AJMC Staff
Ruxolitinib cream, to be sold under the name Opzelura, is the first topical Janus kinase inhibitor cream for the treatment of atopic dermatitis.
ICER Review of AD Therapies Narrowly Supports JAK Inhibitors, Depending on Safety
August 19th 2021

ICER Review of AD Therapies Narrowly Supports JAK Inhibitors, Depending on Safety

Laura Joszt, MA
A review of therapies for atopic dermatitis (AD) found adequate net health benefit for new treatments. However, safety remains a concern for the Janus kinase (JAK) inhibitors.
graphic of patients and doctors
July 17th 2021

Increased Mortality Seen Among Patients With Concomitant AD, Asthma

Gianna Melillo
Researchers assess mortality rates among those with just asthma, just atopic dermatitis, and individuals with both conditions in Denmark.
evaluating dupilumab in a value based health plan
May 10th 2021

Evaluating Dupilumab for Placement in a Value-Based Health Plan

Larry Hanover
Dupilumab is effective for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, but a recent presentation noted the payer challenge in placing the biologic in an optimal tier.
Retrospective Study Examines Dupilumab Performance in Asian Youth Population
April 17th 2021

Retrospective Study Examines Dupilumab Performance in Asian Youth Population

AJMC Staff
Patients had atopic dermatitis for nearly 10 years before starting the biologic therapy.
Mother and child discussing chart with doctor
April 9th 2021

Maternal History of Asthma Drives Risk of Atopic Dermatitis for Their Children

Jaime Rosenberg
Children who were born to women with a history of asthma had a 45% increased risk of being diagnosed with atopic dermatitis/eczema up to age 8 years.
Dermatologist examining patient
March 31st 2021

Patient Evaluation Scarce Among Dermatologists in France Treating Atopic Dermatitis

Larry Hanover
A survey in France found that systemic medications are used by only half of dermatologists in treating atopic dermatitis, with methotrexate used more than cyclosporine.
<1
...
345678>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo